Objective: To assess umbilical artery lactate levels and perinatal outcomes among women with and without HIV infection.
| INTRODUCTION
The burden of HIV among pregnant women in South Africa is estimated to be approximately 30%. 1 
Prenatal testing for HIV in South
Africa is routine, occurring at a rate of at least 95%, 2 and prevention of mother-to-child transmission (PMTCT) programs are almost ubiquitous in prenatal care. 3 In 2014, South Africa followed the 2010 WHO Guidelines for managing maternal HIV in pregnancy with highly active antiretroviral treatment (HAART) administered to women with a CD4 count lower than 350 × 10 6 cells/L. 4 Women with a CD4 count higher than 350 × 10 6 cells/L received antiretroviral (ARV) prophylaxis for PMTCT, including azidothymidine during pregnancy and nevirapine during delivery.
Alongside maternal HIV infection, South Africa has a high perinatal mortality rate of 33.4 per 1000 deliveries. 1 A significant contributor to this perinatal mortality rate is intrapartum and neonatal death, which often results from intrapartum hypoxia and acidosis. 5 Furthermore,
there is an increase in intrapartum asphyxia-related neonatal death among women infected with HIV in South Africa. 6 Because one-third of pregnant women in South Africa have HIV, it is important that clinicians have an understanding the adverse maternal and perinatal outcomes that can occur.
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It was considered that maternal HIV status might play a role in intrapartum acidosis in settings where the burden of HIV is large and adverse perinatal outcomes are common. 7 In addition, the use of antiretroviral therapy (ART) in pregnancy might affect the measurement of acidosis. A previous study 8 found that umbilical artery lactate is an inexpensive and effective way to measure acidosis in the clinic and can be used in the assessment of neonatal outcome.
Consequently, the aim of the present prospective cohort study was to assess umbilical artery lactate results (as a measure of acidosis) and intrapartum and neonatal outcomes among women with and without HIV who were delivering in a large tertiary unit in South Africa. The present study cohort was part of a larger uncontrolled, beforeand-after study, the details of which have been presented elsewhere.
| MATERIALS AND METHODS

9
The full protocol of the larger study is available on request.
For all patients, the umbilical artery was sampled immediately after delivery from a double-clamped segment of cord. Umbilical artery lactate was measured using a handheld meter (Roche Accutrend Plus;
Roche, Rotkreuz, Switzerland) with a demonstrated coefficient of variation of 1.8%-3.0%.
10
For the present study, data were collected from the birth registry and patient case files. 
| RESULTS
During the study period, there were 4668 deliveries at Kalafong The maternal characteristics of the study cohort by HIV status are presented in Table 1 between infected and non-infected women (P=0.529) ( Table 2 ). In addition, there was no difference in the frequency of suspected fetal distress, as determined by cardiotocography (P=0.752) ( 
| DISCUSSION
To the best of our knowledge, the present study is the largest to compare umbilical artery lactate after delivery between patients with and without HIV infections. Among the 897 women and neonates included in the analysis, there were no differences in umbilical artery lactate levels, mode of delivery, or neonatal outcomes between the two groups. This objective measurement of acidosis, coupled with the lack of difference between the two study groups, supports the current protocol whereby intrapartum management of women with HIV in a setting such as South Africa does not differ from that of women without HIV in terms of intrapartum fetal monitoring.
In the study setting, lactate was used as a measure of acidosis; this differs from the widely accepted gold standard of umbilical cord pH. 12 However, lactate has been shown to be an accurate measure of acidosis 8 that can easily be determined with a handheld point-of-care
device. The mean lactate levels in both groups in the present study were similar to those reported in another large cohort study
13
; however, nearly one-third of participants in the present study delivered a neonate with a umbilical artery lactate level higher than 5.45 mmol/L.
This varies from the findings of White et al., 13 who found that only 13% of neonates had an umbilical artery lactate level above the 95% centile when they introduced universal sampling. This discrepancy is likely to be reflective of perinatal outcomes in the present study unit as a whole (for both women with and without HIV); by way of example, 
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the frequency of early neonatal death for all neonates with delivery weight greater than 500 g was 0.2% in the study of White et al., 14 whereas it is 16.7% in provincial tertiary units (including the present study unit) in South Africa. an increase in intrapartum asphyxia-associated neonatal deaths. By contrast, there was no difference in the rate of suspected fetal distress or high umbilical artery lactate levels in the present study. Moreover, women with HIV in the present study were older and had greater parity-two factors that have often been associated with adverse perinatal outcomes. 15 This difference between the current study and others could be due to the number of women enrolled or the fact that the study unit is a tertiary obstetric unit with the resources to respond to clinically acute situations. Although the present study was not powered to predict mortality, the lack of objective evidence for a higher incidence of hypoxia among patients with HIV is reassuring. Notably, no differences in delivery weight or preterm delivery rate were observed among women with HIV, both of which have frequently been cited as concerns of prophylaxis and HAART use in early pregnancy 16, 17 ; however, it should be noted that there was no information on when the study participants commenced treatment regimens.
Evidence regarding whether ART in pregnancy is associated with hyperlactemia in neonates is conflicting, 15 although it seems that ART is unlikely to be associated with pathologic hyperlactemia.
16
Consistent with this, El-Beitune et al. 18 did not find any impact of treatment on umbilical cord gas pH or base excess. This finding was replicated in the present study, where the vast majority of patients with known HIV infections were receiving ARV prophylaxis or HAART, and the lactate outcomes for their neonates were comparable to those of women without HIV. Here, it is suggested that umbilical artery lactate sampling in a unit with a high prevalence of HIV can be introduced without concern of ART impacting on the results.
CD4 counts were available for almost 90% of the study cohort. Kalafong hospital is a tertiary unit in a middle-income country;
consequently, the findings are not applicable to all settings with a high HIV burden. Nevertheless, there are many units within South
Africa where the use of umbilical artery lactate measurements could be considered as a tool for assessing intrapartum care and neonatal outcomes, 21 and the present study data indicate that the inclusion of patients with HIV infections in this process would be acceptable.
The vast majority of individuals infected with HIV live in low-and middle-income countries; consequently, there will be other settings where the distribution of HIV and perinatal outcomes will be similar and where the present evidence can be applied to the assessment of intrapartum care.
The present study had strengths; the large prospective cohort had an HIV rate reflective of the South African population, and, because all women were eligible for inclusion in the study, the perinatal outcomes are likely to reflect those of an unselected population. Additionally, the lactate cutoff used to indicate adverse outcomes was robust, being similar to that found in a previous large high-income country cohort.
14
The study had some limitations. First, some HIV status data were missing; however, given the large sample numbers and that fact that the missing HIV status corresponded to less than 5% of women, it is unlikely that these data would markedly changes the findings. Second, although the cohort was large, it did not capture all deliveries within the study period. Third, there were no paired samples to confirm that the umbilical artery lactate samples were arterial, as previously discussed 9 ; however, the lactate cutoff values have been replicated in other large cohort studies 9, 22 and there is a well-documented positive association between venous lactate and the prediction of arterial lactic acidemia.
In conclusion, umbilical artery lactate-as an objective measure of intrapartum acidosis-and delivery and perinatal outcomes were found to be comparable between women who were and were not infected with HIV in a South African setting.
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